Last updated: October 23, 2022
Sponsor: Gangnam Severance Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
N/ATreatment
N/AClinical Study ID
NCT05088564
3-2021-0084
Ages > 20 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- pylorus-preserving pancreaticoduodenectomy
- ECOG scale 0-1
- Age > 19
- Appropriate organ function as below i.WBC : ≥2500 mm3, ≤14000 mm3 ii.Hemoglobin : ≥9.0g/dL iii.Platelet : ≥100,000 mm3 iv.Total bilirubin : ≤2.0 mg/dL (except for occlusivejaundice) v.Creatinine : ≤2.0 mg/dL
- patient who can understand and sign the informed consent
Exclusion
Exclusion Criteria:
- previous history of gastrectomy
- ulcerative scar around ampulla of duodenum on endoscopy
- previous history of upper abdomen surgery (open)
- Emergency
- Severe ischemic heart disease
- Severe hepatic failure by liver cirrhosis or hepatitis
- Severe respiratory failure that requires oxygene inhalation
- Chronic renal failure that requires hemodialysis
- Expecting combine resection of other organ
- Immunosuppressive therapy
- Accompanying cancer with potential for adverse events
- Severe psychologic or neurologic disease
- drug or alcohol addiction
Study Design
Total Participants: 180
Study Start date:
April 23, 2021
Estimated Completion Date:
April 22, 2024
Study Description
Connect with a study center
Gangnam Severance Hospital
Seoul,
Korea, Republic ofActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.